Ipsen to Present Phase II Data on Corabotase at SCALE Symposium 2026
Ipsen announced on Thursday the presentation of Phase II data for corabotase, an experimental molecule classified as the first of a new therapeutic class called recombinant neuro-inhibitor (RNI). The results, which concern the treatment of glabellar lines, will be presented at the SCALE symposium on May 16, 2026.
Corabotase (IPN10200) was developed using advanced protein engineering techniques and Ipsen's proprietary manufacturing platform. The molecule combines an active catalytic domain with an enhanced affinity binding domain, each element deliberately optimized to increase receptor affinity, improve absorption, and enhance resistance to degradation.
The recognition of corabotase as the first molecule of a new therapeutic class by the WHO and USAN reflects its scientific novelty and Ipsen's historic positioning in neuroscience, according to Christelle Huguet, Executive Vice President and Director of R&D at the group.
LANTIC Trial: Ongoing Multi-Indication Program
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The LANTIC trial (n = 727) assesses the safety and efficacy of corabotase in three aesthetic indications concerning moderate to severe upper facial lines: glabellar lines, forehead lines, and lateral canthal lines. The study is structured in three stages, with Phase II comparing corabotase to a placebo and Dysport.
In September 2025, Ipsen reported positive Phase II data from the first stage, confirming a differentiated clinical profile for corabotase in glabellar lines, with a rapid onset of action and a clinically sustained duration of effect. Proof of concept data for the other two aesthetic indications are expected later in 2026. Beyond LANTIC, an extensive Phase II and Phase III clinical program is advancing corabotase in multiple aesthetic and therapeutic indications.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
